A300E-BiTE

N/A

Report date: 2026/03/19 16:59:48

Base Information

Drug NameA300E-BiTE

Drug Alias NameA-300-E-BiTEA300E-BiTE

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionDisintegrin and metalloproteinase domain-containing protein 17 inhibitorsAnti-CD3

TargetsT cell surface glycoprotein CD3Disintegrin and metalloproteinase domain-containing protein 17

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermany

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesChristian-Albrechts-University of Kiel

China Registration ClassN/A

Develop Information

Active CompaniesChristian-Albrechts-University of Kiel

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A